Cargando…

Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer

PURPOSE: Ferritin is a protein that plays an important role in iron metabolism, it consists of two subunits: heavy chain (FTH) and light chain (FTL). Elevated expression of FTL is observed in multiple malignancies. Recent studies have found that the frequency of circulating autoantibody against FTL...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Pengfei, Wang, Keyan, Ma, Jie, Cao, Xiaoqin, Zhao, Jiuzhou, Zhao, Chengzhi, Guo, Yongjun, Ye, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976487/
https://www.ncbi.nlm.nih.gov/pubmed/35378780
http://dx.doi.org/10.2147/JHC.S352057
_version_ 1784680580438294528
author Ren, Pengfei
Wang, Keyan
Ma, Jie
Cao, Xiaoqin
Zhao, Jiuzhou
Zhao, Chengzhi
Guo, Yongjun
Ye, Hua
author_facet Ren, Pengfei
Wang, Keyan
Ma, Jie
Cao, Xiaoqin
Zhao, Jiuzhou
Zhao, Chengzhi
Guo, Yongjun
Ye, Hua
author_sort Ren, Pengfei
collection PubMed
description PURPOSE: Ferritin is a protein that plays an important role in iron metabolism, it consists of two subunits: heavy chain (FTH) and light chain (FTL). Elevated expression of FTL is observed in multiple malignancies. Recent studies have found that the frequency of circulating autoantibody against FTL (anti-FTL) increased significantly in hepatocellular carcinoma (HCC). The aim of this study is to verify circulating anti-FTL as a biomarker for the early detection of HCC. PATIENTS AND METHODS: A total of 1565 participants were enrolled and assigned to two independent validation cohorts, including 393 HCC patients, 379 liver cirrhosis (LC) patients, 400 chronic hepatitis (CH) patients, and 393 healthy subjects. The concentration of serum anti-FTL was measured by indirect Enzyme-Linked Immunosorbent Assay (ELISA). Kruskal–Wallis test was used to compare anti-FTL concentrations between HCC group and three control groups. Percentile 95 of anti-FTL absorbance value of healthy group was selected as the cut-off value to calculate the positive rate in each group. The area under receiver operating characteristic curve (AUC) was used to quantitatively describe its diagnostic value. RESULTS: The median concentration of anti-FTL in HCC patients was higher than that in CH patients and healthy subjects, but there was no difference between HCC patients and LC patients. Further analysis showed that there was no difference between early stage LC, advanced stage LC, Child-Pugh A HCC, Child-Pugh B HCC and Child-Pugh C HCC. The positive rate of anti-FTL was 12.2% (48/393) in HCC, 13.5% (51/379) in LC, 6.3% (25/400) in CH and 5.1% (20/393) in healthy subjects, respectively. The AUC of anti-FTL to distinguish LC from CH or healthy subjects were 0.654 (95% CI: 0.615–0.692) and 0.642 (95% CI: 0.602–0.681), respectively. CONCLUSION: Anti-FTL is not a biomarker for the early diagnosis of HCC due to specificity deficiency, but may be helpful for the early detection of LC.
format Online
Article
Text
id pubmed-8976487
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-89764872022-04-03 Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer Ren, Pengfei Wang, Keyan Ma, Jie Cao, Xiaoqin Zhao, Jiuzhou Zhao, Chengzhi Guo, Yongjun Ye, Hua J Hepatocell Carcinoma Original Research PURPOSE: Ferritin is a protein that plays an important role in iron metabolism, it consists of two subunits: heavy chain (FTH) and light chain (FTL). Elevated expression of FTL is observed in multiple malignancies. Recent studies have found that the frequency of circulating autoantibody against FTL (anti-FTL) increased significantly in hepatocellular carcinoma (HCC). The aim of this study is to verify circulating anti-FTL as a biomarker for the early detection of HCC. PATIENTS AND METHODS: A total of 1565 participants were enrolled and assigned to two independent validation cohorts, including 393 HCC patients, 379 liver cirrhosis (LC) patients, 400 chronic hepatitis (CH) patients, and 393 healthy subjects. The concentration of serum anti-FTL was measured by indirect Enzyme-Linked Immunosorbent Assay (ELISA). Kruskal–Wallis test was used to compare anti-FTL concentrations between HCC group and three control groups. Percentile 95 of anti-FTL absorbance value of healthy group was selected as the cut-off value to calculate the positive rate in each group. The area under receiver operating characteristic curve (AUC) was used to quantitatively describe its diagnostic value. RESULTS: The median concentration of anti-FTL in HCC patients was higher than that in CH patients and healthy subjects, but there was no difference between HCC patients and LC patients. Further analysis showed that there was no difference between early stage LC, advanced stage LC, Child-Pugh A HCC, Child-Pugh B HCC and Child-Pugh C HCC. The positive rate of anti-FTL was 12.2% (48/393) in HCC, 13.5% (51/379) in LC, 6.3% (25/400) in CH and 5.1% (20/393) in healthy subjects, respectively. The AUC of anti-FTL to distinguish LC from CH or healthy subjects were 0.654 (95% CI: 0.615–0.692) and 0.642 (95% CI: 0.602–0.681), respectively. CONCLUSION: Anti-FTL is not a biomarker for the early diagnosis of HCC due to specificity deficiency, but may be helpful for the early detection of LC. Dove 2022-03-29 /pmc/articles/PMC8976487/ /pubmed/35378780 http://dx.doi.org/10.2147/JHC.S352057 Text en © 2022 Ren et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ren, Pengfei
Wang, Keyan
Ma, Jie
Cao, Xiaoqin
Zhao, Jiuzhou
Zhao, Chengzhi
Guo, Yongjun
Ye, Hua
Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer
title Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer
title_full Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer
title_fullStr Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer
title_full_unstemmed Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer
title_short Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer
title_sort autoantibody against ferritin light chain is a serum biomarker for the detection of liver cirrhosis but not liver cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976487/
https://www.ncbi.nlm.nih.gov/pubmed/35378780
http://dx.doi.org/10.2147/JHC.S352057
work_keys_str_mv AT renpengfei autoantibodyagainstferritinlightchainisaserumbiomarkerforthedetectionoflivercirrhosisbutnotlivercancer
AT wangkeyan autoantibodyagainstferritinlightchainisaserumbiomarkerforthedetectionoflivercirrhosisbutnotlivercancer
AT majie autoantibodyagainstferritinlightchainisaserumbiomarkerforthedetectionoflivercirrhosisbutnotlivercancer
AT caoxiaoqin autoantibodyagainstferritinlightchainisaserumbiomarkerforthedetectionoflivercirrhosisbutnotlivercancer
AT zhaojiuzhou autoantibodyagainstferritinlightchainisaserumbiomarkerforthedetectionoflivercirrhosisbutnotlivercancer
AT zhaochengzhi autoantibodyagainstferritinlightchainisaserumbiomarkerforthedetectionoflivercirrhosisbutnotlivercancer
AT guoyongjun autoantibodyagainstferritinlightchainisaserumbiomarkerforthedetectionoflivercirrhosisbutnotlivercancer
AT yehua autoantibodyagainstferritinlightchainisaserumbiomarkerforthedetectionoflivercirrhosisbutnotlivercancer